Literature DB >> 6316845

Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.

D Cohen, G B Appel, B Scully, H C Neu.   

Abstract

The pharmacokinetic parameters of ceftriaxone in eight patients with end-stage renal disease were determined during dialysis and during the interdialysis period. The mean half-life, clearance, and apparent volume of distribution during dialysis were 16 h, 722 ml/h, and 16.7 liters, respectively. During the interdialysis period, the half-life was 14 h, clearance was 739 ml/h, and volume of distributions was 14 liters. Individual variability in plasma concentrations occurred even in patients with apparently normal hepatic function. Based on these parameters, a dose of 1 g every 24 h would yield concentrations in excess of the concentrations needed to inhibit most gram-positive and gram-negative aerobic species.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6316845      PMCID: PMC185368          DOI: 10.1128/AAC.24.4.529

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 2.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

3.  Multiple intravenous dose pharmacokinetics of ceftriaxone in man.

Authors:  I H Patel; K Miller; R Weinfeld; J Spicehandler
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

4.  Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life.

Authors:  K Stoeckel
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

5.  Clinical study of Rocephin, a 3d generation cephalosporin, in various septicaemias.

Authors:  V Ghosen; R Chamali; O Bar-Moshe; P Stenier
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

6.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

7.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

8.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  9 in total
  20 in total

1.  Clearance of ceftriaxone in critical care patients with acute renal failure.

Authors:  G Heinemeyer; J Link; W Weber; V Meschede; I Roots
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 2.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

5.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 6.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

7.  Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score.

Authors:  Kazuhiko Nakaharai; Yohei Sakamoto; Kenichiro Yaita; Yukihiro Yoshimura; Shun Igarashi; Natsuo Tachikawa
Journal:  Eur J Clin Pharmacol       Date:  2016-04-28       Impact factor: 2.953

8.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients.

Authors:  R Van Dalen; T B Vree; I M Baars
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

10.  The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults.

Authors:  Satofumi Iida; Haruki Kinoshita; Takehiko Kawanishi; Masahiro Hayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.